Supernus Pharmaceuticals SUPN Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's weighted average exercise price of outstanding options?
- Supernus Pharmaceuticals (SUPN) reported weighted average exercise price of outstanding options of $35.04 in Q1 2026.
- How has Supernus Pharmaceuticals's weighted average exercise price of outstanding options changed year-over-year?
- Supernus Pharmaceuticals's weighted average exercise price of outstanding options increased by 13.0% year-over-year, from $31.01 to $35.04.
- What is the long-term trend for Supernus Pharmaceuticals's weighted average exercise price of outstanding options?
- Over 2 years (2023 to 2025), Supernus Pharmaceuticals's weighted average exercise price of outstanding options has grown at a 5.7% compound annual growth rate (CAGR), from $29.20 to $32.63.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.